Motorola Solutions Inc vs Vaxcyte Inc. Common Stock — how do they compare? Motorola Solutions Inc trades at $449.41 (market cap $74.31B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Motorola Solutions Inc is far larger — about 7.1× Vaxcyte Inc. Common Stock's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 101 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MSI | PCVX | |
|---|---|---|
Market Cap | $74.31B | $10.51B |
Volume | 847,711 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $491.24 | $73.82 |
52-Week Low | $363.83 | $40.32 |
Typical Hold Time | 101 Days | 0 Days |
Enterprise Value | $83.22B | $9.14B |
Dividend Yield | 1.08% | — |
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $451.49, up 1.19% with a neutral technical outlook. The stock shows strong fundamentals with consistent earnings beats, a record $15.6B backlog (Zacks, 2026-09-28), and robust profitability (17.44% net margin). Recent acquisitions like D-Fend Solutions expand its security footprint, while a $2B share repurchase boost signals confidence. Valuation ratios remain elevated with P/E at 35.38.
Outlook is positive driven by contract wins and AI integration, but high valuation and significant investing cash outflows ($-5.16B in 2025) pose risks. Analyst consensus is bullish (70.59% Buy) with a $525.86 price target, implying 16% upside. Key risks include execution of acquisitions and debt levels (debt-to-asset 47.29% in 2025).
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →